Norwegian-based clinical stage company Targovax has reported positive overall survival data from the Phase I/II clinical trial (CTTG01-01) of TG01 in resected pancreatic cancer patients.
A part of the firm's TG-Peptide platform, TG01 is a peptide based anti-cancer vaccine developed for the treatment of RAS mutations to slow cancer progression, as well as improve survival, safety and tolerability.
Conducted in four centres in the UK and Norway, the Phase I/II trial is an open label study designed to evaluate TG01 co-administered with GM-CSF in combination with gemcitabine.
Targovax chief medical officer Magnus Jäderberg said: "We are encouraged by the two-year overall survival rate of patients treated with TG01 in this trial, versus the expected rate from published historical data when treating with gemcitabine alone, the current standard of care.
"Whilst acknowledging the small size of this first patient cohort and the lack of a control arm, we are encouraged by what seems to be a signal of efficacy in this highly malignant and difficult to treat cancer."
The trial evaluated a total of 19 patients in the first cohort, who were administered TG01 / GMCSF in combination with gemcitabine.
The primary objective of the study is the evaluation of safety and immune activation, while the secondary objective includes assessment of efficacy at two years.
The results from the trial indicated that 13 patients were still alive after two years if survival is counted from the time of resection, which occurred on average two months before the first treatment, or 12 were alive if counted from the time of first treatment.
Image: Micrograph of a type of pancreatic cancer, pancreatic ductal adenocarcinoma. Photo: courtesy of KGH/Wikipedia.